Precision Lung Cancer Logo

Day One: Tuesday October 22, 2019

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Lung Cancer Immunotherapy

8:30

Precision Medicine: Predicting IO Efficacy


Giovanni Abbadessa

Head of Oncology Early Development


Sanofi

9:15

Advancing Biomarker Discovery and Screening with FirePlex® Technology

 

Ivona Kelley

Director of sales, Multiplex

 

abcam

9:30

Bintrafusp alfa, a new class of immunotherapy targeting simultaneously TGF-b and PD-L1 in lung cancer

Italia Grenga
Medical Director

 

 

EMD Serono, Inc.

10:00

A game of clones: Multidisciplinary science elucidates the challenge of intratumor heterogeneity in non-small cell lung cancer

 

Aaron Goldman

Director, R&D

 

Farcast Biosciences

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:30

Understanding Immune Checkpoint TIM-3 Biology and Anti-TIM-3 Antibody for Cancer Immunotherapy

 

Xiaomo Jiang

Investigator III

 

Novartis Institutes for BioMedical Research, Immuno-Oncology

LUNCH & NETWORKING

12:00

1:00

TAKEDA: Joining the Evolution in Lung Cancer

 

Rachael Brake

Global Program Lead / Vice President

 

Takeda Oncology

1:30

Targeting lung cancer using CRISPR-Allogeneic CAR-T Cell Therapy

 

Mary-Lee Dequeant

Program Lead Scientist


CRISPR Therapeutics

2:00

The Plinabulin/Docetaxel combination is an Immuno/Chemo Combination with the Potential of Having Superior Efficacy, Safety and QoL over Docetaxel Monotherapy in 2nd and 3rd line NSCLC.


Ramon Mohanlal

EVP R&D, Chief Medical Officer


BeyondSpring

AFTERNOON REFRESHMENTS & NETWORKING

2:30

3:00

Clinical development of GITR based immunotherapy.

 

Girish Naik

Medical Director - Immuno-Oncology

Leap Therapeutics

3:30

Selective drugging of the antigen-specific T cell repertoire via the Immuno-STAT Biologics platform

 

Saso Cemerski

Senior Director, Translational Immunology

 

Cue Biopharma

4:00

Current & Future Application of the UNITE Platform in Cancer Immunotherapy

 

Yan Su

Business Development Advisor

Immunomic Therapeutics

 

4:30

PROTAC drugs: New Ligases and Novel PROTAC Approaches, Road Less Travelled

 

Tauseef Butt

President and CEO

 

Progenra, Inc.

DRINKS RECEPTION & NETWORKING

5:00

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF